Precision Vaccines Program | Approach & Current Projects

The paradigm for the cycle of precision vaccinology.

Figure Legend: Paradigm for the cycle of precision vaccinology. Development of precision vaccines may include system biology analysis of biosamples from clinical trials to define molecular pathways that correlate with immunogenicity, thereby generating new hypotheses; use of in vitro systems for hypothesis testing; and characterization of population-specific responses, thereby informing use of appropriate animal models and targeted clinical trials.

The PVP is the focal point of several large projects including:

  1. Human Immunology Project Consortium (HIPC) study entitled “Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity,” undertaken as part of the Expanded Program on Immunization Consortium (EPIC). This study with clinical sites in Boston, USA, The Gambia, and Papua New Guinea, employs systems biology to characterize vaccine-induced molecular patterns (“signatures”) that correspond to vaccine-mediated protection will accelerate development and optimization of vaccines optimized to protect the very young against infections of major global health importance. Our collaborative international team includes multiple Precision Vaccines Network members: Arce, Bennike, Ben Othman, Brinkman, Darboe, Fatou, Hancock, Idoko, Kampmann, Kollmann, Kraft, Lee, Levy, Marchant, Ozonoff, Pomat, Richmond, Sanchez-Schmitz, Shannon, Steen, Tebbutt, van den Biggelaar, van Haren, Smolen, and Vo among many others.
  2. Immunophenotyping of a Coronavirus Cohort (IMPACC). This national study will follow up to 2,000 adult study participants admitted to hospital with COVID for 1 year. As outlined in this news story, the IMPACC study will capture clinical data as well as multiple longitudinal time-points this study will define molecular signatures of COVID severity and outcome thereby informing new approaches to diagnose, treat and prevent this disease.
  3. Adjuvant Discovery & Development contracts led by PVP faculty member David J. Dowling: https://www.nih.gov/news-events/news-releases/nih-awards-seven-new-vaccine-adjuvant-discovery-contracts.